Has ivermectin been linked to acute liver failure or chronic liver disease in medical case reports?

1. The baseline view from drug safety authorities: rare, usually mild, no established chronic or fulminant pattern

Reference compendia and hepatology reviews summarize decades of experience with ivermectin and conclude that reported liver test abnormalities have been mostly mild and self‑limited and that ivermectin “has not been associated with acute liver failure or chronic liver injury” in routine therapeutic contexts ^{[1] [6]}.

2. The counterpoint in the medical literature: documented case reports of severe liver injury

Despite the reassuring baseline, case literature documents at least one well‑described severe hepatitis temporally linked to a single therapeutic dose in a patient treated for Loa loa, with liver biopsy showing confluent necrosis and inflammation consistent with drug‑induced liver disease — reported as “the first case of ivermectin‑induced severe hepatitis” in 2006 ^{[2] [3] [7]}, and later case reports and clinical reviews cite this event when cataloguing ivermectin‑associated DILI ^[8].

3. Cases tied to misuse, overdose or complex clinical pictures that escalated to liver failure

Beyond single‑dose therapeutic reports, several modern case reports implicate excessive or non‑prescribed use — including self‑administration of veterinary formulations or escalating high doses for COVID‑19 prophylaxis — in acute severe liver injury and at least one fulminant liver failure requiring transplant described in case literature ^{[9] [4] [5]}. Pharmacovigilance data from VigiBase flagged hepatic disorders in a subset of ivermectin reports, including hepatitis and cholestasis, some tied to COVID‑19 use ^[5].

4. How to reconcile the disparity: rarity, causality complexity, and real‑world misuse

The evidence picture is one of rarity and complexity: population‑level safety resources emphasize no established link to chronic liver disease or a reproducible acute liver failure syndrome under normal dosing ^{[1] [6]}, while clinicians and case authors warn that idiosyncratic DILI can occur and that misuse/overdose or co‑factors (other drugs, underlying disease, infections) complicate causality; pharmacovigilance signals and case reports thus serve as warnings rather than evidence of a common, dose‑predictable hepatotoxin ^{[5] [8] [10]}.

5. The role of the pandemic, misinformation, and reporting bias

The COVID‑19 pandemic changed exposure patterns: increased off‑label and veterinary‑product use led to more reported adverse events and several high‑visibility case reports of severe hepatic injury after non‑standard dosing or formulations, raising both genuine safety concerns and the possibility of reporting bias concentrated on misuse rather than supervised medical use ^{[4] [9] [11]}.

6. Bottom line, evidence limits, and clinical implications

The balanced conclusion is this: controlled, recommended ivermectin use has not been shown to cause a reproducible syndrome of acute liver failure or chronic liver disease at the population level ^[1], but isolated cases of severe DILI — including severe hepatitis and instances linked to overdose or prolonged unsupervised use that progressed to liver failure — have been documented in peer‑reviewed reports and pharmacovigilance databases ^{[2] [3] [4] [5]}. The literature cannot precisely quantify risk or prove causality in every case; clinicians should monitor liver tests when prescribing in higher‑risk contexts and public health messaging should highlight the dangers of off‑label, high‑dose, or veterinary ivermectin use ^{[1] [5] [4]}.